US 11,918,621 B2
Methods and treatments using toll-like receptor agonists to mitigate hematopoietic myeloid loss, increase gastrointestinal recovery and reduce tumor growth
Jenny P.-Y. Ting, Chapel Hill, NC (US); Willie June Brickey, Durham, NC (US); Hao Guo, Hillsborough, NC (US); and Cathryn Julia Robbins, Redwood City, CA (US)
Assigned to The University of North Carolina at Chapel Hill, Chapel Hill, NC (US)
Appl. No. 16/761,063
Filed by The University of North Carolina at Chapel Hill, Chapel Hill, NC (US)
PCT Filed Nov. 19, 2018, PCT No. PCT/US2018/061720
§ 371(c)(1), (2) Date May 1, 2020,
PCT Pub. No. WO2019/099967, PCT Pub. Date May 23, 2019.
Claims priority of provisional application 62/587,646, filed on Nov. 17, 2017.
Prior Publication US 2020/0282006 A1, Sep. 10, 2020
Int. Cl. A61K 38/08 (2019.01); A61K 9/00 (2006.01); A61P 35/00 (2006.01)
CPC A61K 38/08 (2013.01) [A61K 9/0019 (2013.01); A61K 9/0053 (2013.01); A61P 35/00 (2018.01)] 5 Claims
 
1. A method of mitigating and/or preventing side effects from chemotherapy in a subject, the method comprising
administering to the subject a therapeutically effective amount of a fibroblast-stimulating lipopeptide 1 (FSL-1),
wherein side effects from chemotherapy are substantially mitigated and/or prevented in the subject.